Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Predicting who is likely or unlikely to respond to checkpoint inhibitors remains a focus for researchers.
This finding from a large study surprised and concerned researchers.
The study followed up with people five to seven years after treatment, allowing the researchers to correlate blood factors with survival.
The new report shows that melanoma is the fifth most commonly diagnosed cancer in the United States among both men and women.
This research offers hope that certain drugs given before metastasis could reduce the number of patients whose cancers progress stage 4.
Acral, uveal, and mucosal melanoma — known collectively as “rare melanomas” — represent a type of black hole for the clinical communit...
A new study shows a sharp drop in melanoma rates in people under 30, but skin cancer rates are still going up in those over 40.
The new documentary follows the pioneering researcher who work helped created checkpoint inhibitor immunotherapy.
Learn about cutting-edge advances in melanoma, the research pipeline, and the latest in melanoma prevention and early detection
While pervasive, the myth that people of color don’t need to worry about skin cancer is entirely untrue.
A public workshop organized by the FDA and MRA
While most gene mutations are harmless, others are not and can spur the formation of cancer.
“It was amazing to see the tumors shrink over time; and if this helps other people in the future, that’s even better.”
MRA has become the largest non-profit funder of melanoma research worldwide, helping to usher in a new paradigm in melanoma treatment.
A study in mice suggests that therapies approved for breast cancer may also combat other types, including colorectal and stomach cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.